Correction to: Clinical Pharmacokinetics and Pharmacodynamics of CSL112 (Clinical Pharmacokinetics, (2023), 62, 4, (541-558), 10.1007/s40262-023-01224-8)

In this article the Table 3 title previously read: “CSL122 summary” should read: “CSL112 summary”. Section 4, Column 2, 2nd paragraph, first sentence, previously read: “The final sample size (n = 18,231) was based on CEC-adjudicated MACE rates and was monitored during the enrollment phase.” It should read: “The final target sample size (n ≈ 18,200) was based on observed blinded MACE rates and was monitored during the enrollment phase.” Section 5, 3rd and 4th sentences previously read: “The study enrollment was completed on November 21, 2022, and the estimated primary endpoint (MACE) completion is expected for March 2023. Furthermore, the end of the study and key secondary endpoints (components of MACE and safety) are scheduled for late December 2023.” It should read: “The study enrollment was completed in November 2022, and the estimated primary endpoint (MACE) completion is expected for March 2023. The trial will remain blinded until after the end of study and completion of the key secondary endpoints in December 2023.”